Company Monitoring Page for Regeneron

job ratings (see below graph) for Regeneron

latest headlines for company on cafepharma

Regeneron, Sanofi Win Approval for Their First Immuno-Oncology Drug
Bloomberg
Sat, 09/29/18 - 12:12 pm
Tags:
Regeneron, Sanofi, Libtayo, immuno-oncology, skin cancer, FDA
3 Drugmakers Not Pleased With Amarin's Fish Oil Triumph
Yahoo/Motley Fool
Thu, 09/27/18 - 10:07 am
Tags:
Amarin, Vascepa, Amgen, Sanofi, Regeneron
FDA to review Regeneron’s Eylea for diabetic retinopathy
Drug Delivery Business News
Thu, 09/13/18 - 11:29 pm
Tags:
Regeneron, FDA, Eylea, diabetic retinopathy
Regeneron will invest $800 million, expand workforce by 1,500
Bizjournals.com
Wed, 09/12/18 - 07:15 pm
Tags:
Regeneron, drug manufacturing, New York
Just a few days after a stumble, FDA OKs 12-week dose for Eylea as Regeneron braces for Novartis attack
Endpoints
Fri, 08/17/18 - 09:28 am
Tags:
FDA, Eylea, Regeneron, Novartis, wet age-related macular degeneration
Teva and Regeneron's Fasinumab Meets Primary and Secondary Endpoints in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip
CP Wire
Thu, 08/16/18 - 10:11 am
Tags:
Teva Pharmaceutical, Regeneron, fasinumab, osteoarthritis
Thu, 08/16/18 - 09:58 am
Tags:
Teva Pharmaceutical, Regeneron, fasinumab, osteoarthritis
Racing Novartis on Eylea rival, the FDA trips up Regeneron at the finish line
Endpoints
Mon, 08/13/18 - 11:39 am
Tags:
Regeneron, Eylea, Novartis, RTH258, wet age-related macular degeneration, FDA
Citing appeals court 'anarchy,' Amgen asks SCOTUS to weigh its PCSK9 patent spat with Sanofi
Fierce Pharma
Thu, 08/9/18 - 03:57 pm
Tags:
Amgen, Sanofi, Regeneron, PCSK9 inhibitors, Supreme Court, Praluent, Repatha
Regeneron And Bluebird Team To Invent New Cell Therapies For Cancer
Forbes
Mon, 08/6/18 - 11:53 am
Tags:
Regeneron, Bluebird Bio, CAR-T, drug discovery, gene therapy, cancer
The Week Ahead In Biotech: Conferences, PDUFA Dates And IPOs
Yahoo/Benzinga
Sun, 08/5/18 - 07:25 pm
Tags:
biotech, IPOs, Pain Therapeutics, Remoxy, Vertex Pharmaceuticals, lumacaftor/ivacaftor, Alnylam, Patisiran, Regeneron, Eylea, Insmed, Paratek, Vaccinex
Regeneron plots DTC advertising and discount push to put Eylea back on track
Fierce Pharma
Fri, 08/3/18 - 11:08 pm
Tags:
Regeneron, Sanofi, Eylea, DTC advertising
Regeneron’s Billionaire Founder Battles The Drug Pricing System
Forbes
Thu, 07/26/18 - 11:44 am
Tags:
Regeneron, Leonard Schleifer, drug pricing
Allergan’s eye contender cannot knock Eylea off its perch
EP Vantage
Sun, 07/22/18 - 12:24 pm
Tags:
Regeneron, Eylea, wet age-related macular degeneration, Allergan, molecular, abicipar
Regeneron, Sanofi show restraint on Dupixent price hike, but Pfizer’s hard charge continues to spur calls for a radical change-up
Endpoints
Tue, 07/3/18 - 12:13 pm
Tags:
Regeneron, Sanofi, Dupixent, drug pricing
Regeneron Focuses on Expanding Eylea’s Diabetic Retinopathy Label
Market Realist
Thu, 06/21/18 - 09:38 am
Tags:
Regeneron, FDA, Eylea, diabetic retinopathy
With $460B in borrowing capacity, will any of the Big-20 biopharmas go after one of the top-5 takeover targets?
Endpoints
Tue, 05/29/18 - 09:22 pm
Tags:
M&A, JNJ, Merck, Pfizer, Gilead Sciences, Amgen, Biogen, Takeda, Regeneron, Alexion
Biopharma M&A: You Ain’t Seen Nothing Yet
Barron's
Fri, 05/25/18 - 09:32 am
Tags:
JNJ, Merck, Pfizer, Gilead Sciences, Amgen, Regeneron, Alexion, M&A
5 takeaways from the first look at cancer's biggest conference
Biopharma Dive
Thu, 05/17/18 - 10:44 pm
Tags:
ASCO, Regeneron, cemiplimab, Keytruda, Opdivo, Merck, Bristol-Myers Squibb, Nektar, NKTR-214, Loxo Oncology, LOXO-292, Jounce Therapeutics, JTX-2011
Are These Disappointing Drugs Back on Track to Billions?
Motley Fool
Sun, 05/6/18 - 01:33 pm
Tags:
PCSK9 inhibitors, Sanofi, Regeneron, Amgen, Praluent, Repatha

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.